Secondary Progressive Multiple Sclerosis (SPMS) Therapeutic and Overview Pipeline Review H2

WiseGuyReports.com adds “Secondary Progressive Multiple Sclerosis (SPMS) – Pipeline Review, H2 2016
” reports to its database.

The report provides comprehensive information on the therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS) and features dormant and discontinued projects.

 

Get Sample Report @ https://www.wiseguyreports.com/sample-request/619266-secondary-progressive-multiple-sclerosis-spms-pipeline-review-h2-2016            

 

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

 

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

 

Scope

– The report provides a snapshot of the global therapeutic landscape of Secondary Progressive Multiple Sclerosis (SPMS)

– The report reviews pipeline therapeutics for Secondary Progressive Multiple Sclerosis (SPMS) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Secondary Progressive Multiple Sclerosis (SPMS) therapeutics and enlists all their major and minor projects

– The report assesses Secondary Progressive Multiple Sclerosis (SPMS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Secondary Progressive Multiple Sclerosis (SPMS)

 

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand important and diverse types of therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS)

– Identify potential new clients or partners in the target demographic

– Develop strategic initiatives by understanding the focus areas of leading companies

– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

– Devise corrective measures for pipeline projects by understanding Secondary Progressive Multiple Sclerosis (SPMS) pipeline depth and focus of Indication therapeutics

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Secondary Progressive Multiple Sclerosis (SPMS) Overview 9

Therapeutics Development 10

Pipeline Products for Secondary Progressive Multiple Sclerosis (SPMS) – Overview 10

Secondary Progressive Multiple Sclerosis (SPMS) – Therapeutics under Development by Companies 11

Secondary Progressive Multiple Sclerosis (SPMS) – Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Secondary Progressive Multiple Sclerosis (SPMS) – Products under Development by Companies 16

Secondary Progressive Multiple Sclerosis (SPMS) – Companies Involved in Therapeutics Development 17

AB Science SA 17

Actelion Ltd 18

Biogen, Inc. 19

F. Hoffmann-La Roche Ltd. 20

Genzyme Corporation 21

Glialogix, Inc. 22

Immune Response BioPharma, Inc. 23

Innate Immunotherapeutics Ltd 24

Kyorin Pharmaceutical Co., Ltd. 25

Mallinckrodt Plc 26

MedDay SA 27

MedImmune, LLC 28

Merck KGaA 29

Meta-IQ ApS 30

Novartis AG 31

Opexa Therapeutics, Inc. 32

Xenetic Biosciences (UK) Limited 33

Secondary Progressive Multiple Sclerosis (SPMS) – Therapeutics Assessment 34

Assessment by Monotherapy Products 34

Assessment by Target 35

Assessment by Mechanism of Action 38

7Assessment by Route of Administration 41

Assessment by Molecule Type 43

Drug Profiles 45

biotin – Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

DC-TAB – Drug Profile 49

Product Description 49

 

Access Report @ https://www.wiseguyreports.com/reports/619266-secondary-progressive-multiple-sclerosis-spms-pipeline-review-h2-2016

                                                                                    

Contact Info:                                                         

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)                                                   

 

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: https://twitter.com/WiseGuyReports

Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Media Contact
Company Name: Wiseguyreports.com
Contact Person: Norah Trent
Email: sales@wiseguyreports.com
Phone: +1 646 845 9349, +44 208 133 9349
City: New York City
State: NY
Country: United States
Website: www.wiseguyreports.com